$CTMX
CytomX Therapeutics Inc

2022 Q3 Form 10-Q Financial Statement

#000095017022014737 Filed on August 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $16.92M $18.17M $17.14M
YoY Change -3.82% 11.52% 7.29%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.49M $11.75M $10.54M
YoY Change -5.37% 25.07% 14.23%
% of Gross Profit
Research & Development $30.37M $31.16M $30.56M
YoY Change 4.2% 19.38% 36.6%
% of Gross Profit
Depreciation & Amortization $623.0K $610.0K $602.0K
YoY Change -8.38% -18.77% 0.33%
% of Gross Profit
Operating Expenses $40.86M $42.91M $41.10M
YoY Change 1.56% 20.89% 30.08%
Operating Profit -$23.94M -$24.74M -$23.97M
YoY Change 5.75% 28.83% 53.36%
Interest Expense $616.0K $262.0K $68.00K
YoY Change 780.0% 495.45% -2.86%
% of Operating Profit
Other Income/Expense, Net $30.00K $296.0K $13.00K
YoY Change -330.77% -460.98% 160.0%
Pretax Income -$23.30M -$24.18M -$23.89M
YoY Change 3.15% 25.68% 53.6%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$23.30M -$24.18M -$23.89M
YoY Change 3.15% 25.68% 53.56%
Net Earnings / Revenue -137.72% -133.14% -139.38%
Basic Earnings Per Share
Diluted Earnings Per Share -$353.4K -$369.0K -$365.2K
COMMON SHARES
Basic Shares Outstanding 65.95M 65.54M 65.39M
Diluted Shares Outstanding 65.91M 65.54M 65.39M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $194.3M $228.2M $262.5M
YoY Change -17.77% -14.28% -33.33%
Cash & Equivalents $95.04M $129.3M $163.5M
Short-Term Investments $99.25M $98.88M $99.04M
Other Short-Term Assets $4.278M $3.591M $4.898M
YoY Change 11.93% -7.85% -10.95%
Inventory
Prepaid Expenses
Receivables $1.712M $1.014M $1.016M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $200.3M $232.8M $268.4M
YoY Change -16.9% -14.11% -32.89%
LONG-TERM ASSETS
Property, Plant & Equipment $5.710M $5.915M $6.093M
YoY Change -8.95% -11.7% -78.92%
Goodwill $949.0K $949.0K $949.0K
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $895.0K $895.0K $902.0K
YoY Change -0.78% -0.67% -71.81%
Total Long-Term Assets $26.21M $27.32M $28.38M
YoY Change -79.87% -79.22% -17.01%
TOTAL ASSETS
Total Short-Term Assets $200.3M $232.8M $268.4M
Total Long-Term Assets $26.21M $27.32M $28.38M
Total Assets $226.5M $260.1M $296.8M
YoY Change -38.99% -35.37% -31.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.176M $1.920M $1.721M
YoY Change 241.42% 9.4% -33.81%
Accrued Expenses $31.34M $31.73M $31.03M
YoY Change 24.53% 64.82% 64.79%
Deferred Revenue $61.33M $65.79M $70.01M
YoY Change -16.1% -9.1%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $97.84M $99.44M $102.8M
YoY Change -1.94% 6.49% 4.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $100.2M $111.9M $125.9M
YoY Change -37.31% -37.15% -33.79%
Total Long-Term Liabilities $100.2M $111.9M $125.9M
YoY Change -37.31% -37.15% -33.79%
TOTAL LIABILITIES
Total Short-Term Liabilities $97.84M $99.44M $102.8M
Total Long-Term Liabilities $100.2M $111.9M $125.9M
Total Liabilities $198.0M $211.4M $228.6M
YoY Change -23.71% -22.14% -20.65%
SHAREHOLDERS EQUITY
Retained Earnings -$605.1M -$581.8M -$557.6M
YoY Change 19.23% 19.98% 19.74%
Common Stock $1.000K $1.000K $1.000K
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $28.47M $48.71M $68.19M
YoY Change
Total Liabilities & Shareholders Equity $226.5M $260.1M $296.8M
YoY Change -38.99% -35.37% -31.63%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$23.30M -$24.18M -$23.89M
YoY Change 3.15% 25.68% 53.56%
Depreciation, Depletion And Amortization $623.0K $610.0K $602.0K
YoY Change -8.38% -18.77% 0.33%
Cash From Operating Activities -$33.84M -$34.24M -$41.31M
YoY Change 13.95% 21.24% 37.99%
INVESTING ACTIVITIES
Capital Expenditures -$410.0K -$412.0K $736.0K
YoY Change 52.99% 329.17% -25.05%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Cash From Investing Activities -$410.0K -$412.0K -$736.0K
YoY Change -104.21% -99.1% -101.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 451.0K 7.000K
YoY Change -100.0% -37.88% -99.99%
NET CHANGE
Cash From Operating Activities -33.84M -34.24M -41.31M
Cash From Investing Activities -410.0K -412.0K -736.0K
Cash From Financing Activities 0.000 451.0K 7.000K
Net Change In Cash -34.25M -34.20M -42.04M
YoY Change 72.46% -53.48% -130.51%
FREE CASH FLOW
Cash From Operating Activities -$33.84M -$34.24M -$41.31M
Capital Expenditures -$410.0K -$412.0K $736.0K
Free Cash Flow -$33.43M -$33.82M -$42.05M
YoY Change 13.6% 20.19% 35.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
dei Document Type
DocumentType
10-Q
CY2022Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
CY2022Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
CY2022Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
CY2021Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
CY2021Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
dei Entity Central Index Key
EntityCentralIndexKey
0001501989
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
CY2021Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
dei Amendment Flag
AmendmentFlag
false
CY2021Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Quarterly Report
DocumentQuarterlyReport
true
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.73
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3521219
dei Entity Address Address Line1
EntityAddressAddressLine1
151 Oyster Point Blvd.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
790000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3591000
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.55
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18056000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4285000
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.55
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
CY2022Q2 us-gaap Liabilities
Liabilities
211378000
CY2021Q4 us-gaap Liabilities
Liabilities
250032000
dei Local Phone Number
LocalPhoneNumber
515-3185
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
dei Security12b Title
Security12bTitle
Common Stock, $0.00001 par value per share
dei Trading Symbol
TradingSymbol
CTMX
CY2022Q2 us-gaap Assets Current
AssetsCurrent
232770000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-242000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
310301000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5915000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5960000
CY2022Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
948000
CY2021Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1021000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
65756492
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-581793000
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37587
dei Entity Registrant Name
EntityRegistrantName
CytomX Therapeutics, Inc.
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
623344000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
129290000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
69262000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
99439000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
205530000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
98875000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
106316000
CY2022Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
95863000
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
65756492
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
99696000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1014000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
125660000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
16076000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-920000
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
65950242
CY2022Q2 us-gaap Goodwill
Goodwill
949000
CY2021Q4 us-gaap Goodwill
Goodwill
949000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17692000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19362000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
895000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
901000
CY2022Q2 us-gaap Assets
Assets
260086000
CY2021Q4 us-gaap Assets
Assets
339411000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1920000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2818000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
31732000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
34236000
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
65787000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
32259000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31159000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1162000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
62000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
65392758
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
65392758
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
631662000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-533724000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
48708000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
89379000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
260086000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
339411000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18165000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16288000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
35302000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26100000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
61718000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48472000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11748000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9393000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22292000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18619000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
42907000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
35493000
us-gaap Operating Expenses
OperatingExpenses
84010000
us-gaap Operating Expenses
OperatingExpenses
67091000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-24742000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-19205000
us-gaap Operating Income Loss
OperatingIncomeLoss
-48708000
us-gaap Operating Income Loss
OperatingIncomeLoss
-34832000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
262000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
44000
us-gaap Investment Income Interest
InvestmentIncomeInterest
330000
us-gaap Investment Income Interest
InvestmentIncomeInterest
112000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
296000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-82000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
309000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-77000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-24184000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-19243000
us-gaap Net Income Loss
NetIncomeLoss
-48069000
us-gaap Net Income Loss
NetIncomeLoss
-34797000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34735000
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.37
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65468638
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-243000
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.37
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63023349
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
58000
CY2021Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.30
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63023349
us-gaap Profit Loss
ProfitLoss
-34797000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
73000
CY2021Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.30
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.73
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
73000
ctmx Depreciation And Amortization Excluding Amortization Of Intangible Assets
DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets
1139000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24427000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19185000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48989000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65542762
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65542762
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65055998
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65055998
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65468638
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
89379000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3370000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-677000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-23885000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
68194000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
91000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
360000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4490000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-243000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-24184000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
48708000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
49803000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
107712000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1023000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3034000
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
4000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-15554000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
146022000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
173000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
518000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3425000
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
58000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-19243000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
130953000
us-gaap Profit Loss
ProfitLoss
-48069000
ctmx Depreciation And Amortization Excluding Amortization Of Intangible Assets
DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets
1278000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
33000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-281000
us-gaap Share Based Compensation
ShareBasedCompensation
7860000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-33272000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-30572000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
99898000
us-gaap Share Based Compensation
ShareBasedCompensation
6459000
ctmx Noncash Lease Expense
NoncashLeaseExpense
-1670000
ctmx Noncash Lease Expense
NoncashLeaseExpense
-1534000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
290000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
133000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-694000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3199000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-6000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1271000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-844000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1173000
ctmx Increase Decrease In Accrued And Other Liabilities Noncurrent
IncreaseDecreaseInAccruedAndOtherLiabilitiesNoncurrent
-4484000
ctmx Increase Decrease In Accrued And Other Liabilities Noncurrent
IncreaseDecreaseInAccruedAndOtherLiabilitiesNoncurrent
-5559000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-75550000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-58139000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1148000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1096000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
113994000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1148000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13000000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
107712000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
458000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1714000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
458000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
109426000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-76240000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
64287000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
206447000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
192776000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
130207000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
257063000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
29000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
54000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
130207000
CY2021Q4 ctmx Cash Cash Equivalents And Investments Amortized Cost Basis
CashCashEquivalentsAndInvestmentsAmortizedCostBasis
266591000
CY2021Q4 ctmx Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax
242000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1. Description of the Business</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">CytomX Therapeutics, Inc. (the “Company”) is a clinical-stage, oncology-focused biopharmaceutical company dedicated to destroying cancer differently. The Company aims to build a commercial enterprise to maximize its impact on the treatment of cancer. The Company is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its Probody® therapeutic technology platform that could meaningfully improve outcomes for cancer patients. Its proprietary and unique Probody technology platform is designed to enable “conditional activation” of antibody-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation. The Company is located in South San Francisco, California and was incorporated in the state of Delaware in September 2010.</span></p>
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
161700000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
206447000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></p>
CY2021Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
266349000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
129290000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
205530000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
256146000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
191859000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
257063000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
192776000
CY2022Q2 ctmx Cash Cash Equivalents And Investments Amortized Cost Basis
CashCashEquivalentsAndInvestmentsAmortizedCostBasis
176832000
CY2022Q2 ctmx Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax
1162000
CY2022Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
175670000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-33272000
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
161650000
ctmx Debt Securities Available For Sale Maturity Period
DebtSecuritiesAvailableForSaleMaturityPeriod
P12M
CY2022Q2 ctmx Accrued Research And Clinical Current
AccruedResearchAndClinicalCurrent
18377000
CY2021Q4 ctmx Accrued Research And Clinical Current
AccruedResearchAndClinicalCurrent
18861000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7109000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9576000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2259000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1468000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3845000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3618000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
142000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
713000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
31732000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
34236000
CY2022Q2 us-gaap Revenues
Revenues
18165000
CY2021Q2 us-gaap Revenues
Revenues
16288000
us-gaap Revenues
Revenues
35302000
us-gaap Revenues
Revenues
32259000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
194922000
ctmx Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12192216
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.42
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3416918
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.55
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
100990
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.98
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1077318
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.93
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14430826
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.13
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4490000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3425000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7860000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6459000
CY2020Q1 ctmx Loss Contingency Answer Affirmative Defenses And Counterclaims Filing Date
LossContingencyAnswerAffirmativeDefensesAndCounterclaimsFilingDate
2020-05-26
CY2020Q1 ctmx Loss Contingency Answer And Counterclaims By Plaintiff Filing Date
LossContingencyAnswerAndCounterclaimsByPlaintiffFilingDate
2020-06-05

Files In Submission

Name View Source Status
0000950170-22-014737-index-headers.html Edgar Link pending
0000950170-22-014737-index.html Edgar Link pending
0000950170-22-014737.txt Edgar Link pending
0000950170-22-014737-xbrl.zip Edgar Link pending
ctmx-20220630.htm Edgar Link pending
ctmx-20220630.xsd Edgar Link pending
ctmx-20220630_cal.xml Edgar Link unprocessable
ctmx-20220630_def.xml Edgar Link unprocessable
ctmx-20220630_htm.xml Edgar Link completed
ctmx-20220630_lab.xml Edgar Link unprocessable
ctmx-20220630_pre.xml Edgar Link unprocessable
ctmx-ex31_1.htm Edgar Link pending
ctmx-ex31_2.htm Edgar Link pending
ctmx-ex32_1.htm Edgar Link pending
ctmx-ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending